Although FDA Commissioner Margaret Hamburg announced a final decision on November 18 to drop breast cancer from the Avastin label, metastatic colorectal cancer continues to be an approved use.

The Avastin® (bevacizumab) label includes the following approved indication:

Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment.

It is important to know that there is currently no approval or evidence for using Avastin alone or in early stage colon or rectal cancer.

Although breast cancer has not traditionally been considered one of the cancers associated with Lynch syndrome, evidence is building that there might be a link.

Breast cancer may actually be with in the spectrum of Lynch cancers.

An Australian team reviewing the pathology of breast cancers in women who carried a mutation for Lynch syndrome ( hereditary non-polyposis colon cancer) found that half of the breast tumors were mismatch repair deficient — a hallmark of Lynch cancers. Read the rest of this entry »